2011
A cost of illness and equality of life study in patients with B-cell chronic lymphocytic leukemia (CLL) in the Netherlands
Publication
Publication
During the last decade the management of CLL was subject to progressive changes in diagnostic and prognostic procedures as well as the development of new alternative treatments. The aim of this study was to assess management, costs, quality of life and survival of CLL patients in daily practice. This information is becoming more important for reimbursement decsions, as new expensive drugs are only reimbursed when the incremental cost-effectiveness ratio lies within existing thresholds. Cost-effectiveness ratios are preferably calculated both in daily practice (or real world) setting and a clinical trial setting.
| Additional Metadata | |
|---|---|
| , , | |
| Bayer Schering Pharma AG | |
| Erasmus School of Health Policy & Management (ESHPM) | |
| hdl.handle.net/1765/39836 | |
| Organisation | Erasmus School of Health Policy & Management (ESHPM) |
|
Holtzer-Goor, K., Bouwmans-Frijters, C., Schaafsma, M., & Uyl-de Groot, C. (2011). A cost of illness and equality of life study in patients with B-cell chronic lymphocytic leukemia (CLL) in the Netherlands. Retrieved from http://hdl.handle.net/1765/39836 |
|
